Temporal trends in cardiovascular burden among patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-49

[2] Ferlay J(2019)Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology J Natl Compr Canc Netw 17 479-505

[3] Siegel RL(2021)EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent Eur Urol 79 243-62

[4] Laversanne M(2006)Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 4448-56

[5] Soerjomataram I(2020)Cardiovascular effects of androgen deprivation therapy in prostate cancer Arterioscler Thromb Vasc Biol 40 e55-3021

[6] Jemal A(2020)Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study J Am Coll Cardiol. 76 2982-52

[7] Mohler JL(2020)Recent global patterns in prostate cancer incidence and mortality rates Eur Urol 77 38-73

[8] Antonarakis ES(2022)Causes of death after prostate cancer diagnosis: a population-based study Oxid Med Cell Longev 2022 8145173-82

[9] Armstrong AJ(2015)Overview of the health care system in Hong Kong and its referential significance to mainland China J Chinese Med Assoc 78 569-57

[10] D’Amico AV(2021)Fragmented QRS is independently predictive of long-term adverse clinical outcomes in asian patients hospitalized for heart failure: a retrospective cohort study Front Cardiovasc Med. 0 1634-90

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-49

[2] Ferlay J(2019)Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology J Natl Compr Canc Netw 17 479-505

[3] Siegel RL(2021)EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent Eur Urol 79 243-62

[4] Laversanne M(2006)Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 4448-56

[5] Soerjomataram I(2020)Cardiovascular effects of androgen deprivation therapy in prostate cancer Arterioscler Thromb Vasc Biol 40 e55-3021

[6] Jemal A(2020)Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study J Am Coll Cardiol. 76 2982-52

[7] Mohler JL(2020)Recent global patterns in prostate cancer incidence and mortality rates Eur Urol 77 38-73

[8] Antonarakis ES(2022)Causes of death after prostate cancer diagnosis: a population-based study Oxid Med Cell Longev 2022 8145173-82

[9] Armstrong AJ(2015)Overview of the health care system in Hong Kong and its referential significance to mainland China J Chinese Med Assoc 78 569-57

[10] D’Amico AV(2021)Fragmented QRS is independently predictive of long-term adverse clinical outcomes in asian patients hospitalized for heart failure: a retrospective cohort study Front Cardiovasc Med. 0 1634-90